Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the fastest growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.


  • Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase (DPP) IV inhibitors as the most valuable oral drug class?
  • Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?
  • Will investments by the pharmaceutical industry in novel FDCs such as Xultophy and Soliqua reap rewards?
  • What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?


Geographies covered

  • United States, EU5, Japan

Primary Research

  • 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other DRG research


  • Prevalence of T2D by country with population-specific diagnosed and drug-treatment rates


  • 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2029, segmented by brands/generics

Emerging therapies

  • Phase III/PR: 7 drugs; coverage of select preclinical, Phase I, and Phase II products
Login to access report